Spicka, Ivan - Resultados de la búsqueda - Depósito Digital de Documentos de la UAB

Buscar colecciones:

Ordenar por:	Mostrar resultados:	Formato de visualización:

Resultados globales: 3 registros encontrados en 0.01 segundos.
Artículos, Encontrados 3 registros

Artículos	Encontrados 3 registros

10 p, 496.7 KB

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma : IKEMA subgroup analysis / Facon, Thierry (Lille University Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Spicka, Ivan (Charles University and General Hospital, Prague, Czech Republic) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital, South Korea) ; Lim, Andrew (Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia) ; Mikala, Gabor (South Pest Central Hospital, Budapest, Hungary) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Yağci, Münci (Gazi University, Ankara, Turkey) ; Cavo, Michele (Bologna University School of Medicine, Italy) ; Yong, Kwee (University College Hospital, London, UK) ; Risse, Marie Laure (Sanofi R&D, Vitry-Sur-Seine, France) ; Asset, Gaëlle (Sanofi R&D, Chilly-Mazarin, France) ; Schwab, Sandrine (Sanofi R&D, Chilly-Mazarin, France) ; Martinez, Gracia (Hospital das Clínicas de São Paulo, Brazil)
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM). [...]
2022 - DOI (Digital Object Identifier)

10.1002/hon.3038
Hematological Oncology, Vol. 40 Núm. 5 (december 2022) , p. 1020-1029

Registro completo -

9 p, 1.5 MB

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma : updated results from IKEMA, a randomized Phase 3 study / Martin, Thomas (University of California at San Francisco, USA) ; Dimopoulos, Meletios (University of Athens, Greece) ; Mikhael, Joseph (Translational Genomics Research Institute. City of Hope Cancer Center, Phoenix, USA) ; Yong, Kwee (University College Hospital, London, UK) ; Capra, Marcelo (Centro Integrado de Hematologia e Oncologia. Hospital Mãe de Deus, Porto Alegre, Brazil) ; Facon, Thierry (Lille University Hospital, France) ; Hajek, Roman (University of Ostrava, Czech Republic) ; Špička, Ivan (Department of Hematology. 1st Faculty of Medicine. Charles University and General Hospital, Prague, Czech Republic) ; Baker, Ross (Murdoch University, Perth, Australia) ; Kim, Kihyun (Sungkyunkwan University School of Medicine, Seoul, South Korea) ; Martinez, Gracia (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil) ; Min, Chang-Ki (The Catholic University of Korea) ; Pour, Ludek (University Hospital Brno (República Txeca)) ; Leleu, Xavier (Service d'Hématologie et Thérapie Cellulaire. CHU and CIC Inserm, France) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital, Seoul, South Korea) ; Suzuki, Kenshi (Japanese Red Cross Medical Center, Tokyo, Japan) ; Casca, France (Ividata Life Science, Levallois-Perret, France) ; Macé, Sandrine (Sanofi, R&D, Chilly-Mazarin, France) ; Risse, Marie-Laure (Sanofi, R&D, Vitry-sur-Seine, France) ; Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety. [...]
2023 - DOI (Digital Object Identifier)

10.1038/s41408-023-00797-8
Blood Cancer Journal, Vol. 13 Núm. 1 (december 2023)

Registro completo -

9 p, 982.6 KB

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics : IKEMA subgroup analysis / Spicka, Ivan (Charles University and General Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Facon, Thierry (Lille University Hospital) ; Martínez, Gracia (Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital) ; Lim, Andrew (Austin and Repatriation Medical Center) ; Mikala, Gabor (South Pest Central Hospital) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Yağci, Münci (Gazi University) ; Cavo, Michele (Università di Bologna) ; Risse, Marie-Laure (Sanofi (França)) ; Asset, Gaëlle (Sanofi (França)) ; Macé, Sandrine (Sanofi (França)) ; Van de Velde, Helgi (Sanofi) ; Yong, Kwee (University College Hospital) ; Universitat Autònoma de Barcelona
Introduction: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. [...]
2022 - DOI (Digital Object Identifier)

10.1111/ejh.13835
European Journal of Haematology, Vol. 109 Núm. 5 (november 2022) , p. 504-512

Registro completo -

Vea también: autores con nombres similares
3	Spicka, I.
3	Špička, I.
3	Špička, Ivan

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.